One-year outcomes in 1,010 unselected patients treated with the PROMUS Element everolimus-eluting stent: the multicentre PROMUS Element European Post-Approval Surveillance Study

Martyn R. Thomas, Ralf Birkemeyer, Peter Schwimmbeck, Victor Legrand, Raul Moreno, Carlo Briguori, Nikos Werner, Ezio Bramucci, Imre Ungi, Gert Richardt, Paul L. Underwood, Keith D. Dawkins

Research output: Contribution to journalArticle

Abstract

AIMS: The PROMUS™ Element™ European Post-Approval Surveillance Study (PE-Prove) is a prospective, open-label, multicentre observational study designed to assess outcomes following PROMUS Element everolimus-eluting stent implantation in an unselected patient population.

METHODS AND RESULTS: A total of 1,010 patients were enrolled at 40 clinical sites in Europe, including 24.9% with medically treated diabetes, 50.0% with Type B2/C lesions, 6.1% with chronic total occlusion, 17.8% with acute myocardial infarction (MI ≤24 hours pre-procedure), and 20.1% with unstable angina. The target lesion was the culprit for ST-segment elevation MI in 7.3% of patients. The one-year, per patient target vessel failure rate was 6.2% (60/975), 3.4% (33) being related to the PROMUS Element stent. Rates of cardiac death, MI, and Academic Research Consortium (ARC) definite/probable stent thrombosis were 1.7%, 3.5%, and 0.6%, respectively. The target vessel revascularisation rate was 3.2% (31/975), 2.1% (20) being related to the PROMUS Element stent.

CONCLUSIONS: In a large and relatively complex group of "real-world" patients, coronary artery revascularisation with the PROMUS Element everolimus-eluting stent provides favourable results with low event rates consistent with those reported for other contemporary drug-eluting stents.

Original languageEnglish
Pages (from-to)1267-1271
Number of pages5
JournalEuroIntervention
Volume10
Issue number11
DOIs
Publication statusPublished - Mar 1 2015

Fingerprint

Stents
Drug-Eluting Stents
Unstable Angina
Multicenter Studies
Observational Studies
Coronary Vessels
Thrombosis
Myocardial Infarction
Everolimus
Research
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

One-year outcomes in 1,010 unselected patients treated with the PROMUS Element everolimus-eluting stent : the multicentre PROMUS Element European Post-Approval Surveillance Study. / Thomas, Martyn R.; Birkemeyer, Ralf; Schwimmbeck, Peter; Legrand, Victor; Moreno, Raul; Briguori, Carlo; Werner, Nikos; Bramucci, Ezio; Ungi, Imre; Richardt, Gert; Underwood, Paul L.; Dawkins, Keith D.

In: EuroIntervention, Vol. 10, No. 11, 01.03.2015, p. 1267-1271.

Research output: Contribution to journalArticle

Thomas, MR, Birkemeyer, R, Schwimmbeck, P, Legrand, V, Moreno, R, Briguori, C, Werner, N, Bramucci, E, Ungi, I, Richardt, G, Underwood, PL & Dawkins, KD 2015, 'One-year outcomes in 1,010 unselected patients treated with the PROMUS Element everolimus-eluting stent: the multicentre PROMUS Element European Post-Approval Surveillance Study', EuroIntervention, vol. 10, no. 11, pp. 1267-1271. https://doi.org/10.4244/EIJY15M01_07
Thomas, Martyn R. ; Birkemeyer, Ralf ; Schwimmbeck, Peter ; Legrand, Victor ; Moreno, Raul ; Briguori, Carlo ; Werner, Nikos ; Bramucci, Ezio ; Ungi, Imre ; Richardt, Gert ; Underwood, Paul L. ; Dawkins, Keith D. / One-year outcomes in 1,010 unselected patients treated with the PROMUS Element everolimus-eluting stent : the multicentre PROMUS Element European Post-Approval Surveillance Study. In: EuroIntervention. 2015 ; Vol. 10, No. 11. pp. 1267-1271.
@article{3b91b8d4fafe485393c708d8074fef01,
title = "One-year outcomes in 1,010 unselected patients treated with the PROMUS Element everolimus-eluting stent: the multicentre PROMUS Element European Post-Approval Surveillance Study",
abstract = "AIMS: The PROMUS™ Element™ European Post-Approval Surveillance Study (PE-Prove) is a prospective, open-label, multicentre observational study designed to assess outcomes following PROMUS Element everolimus-eluting stent implantation in an unselected patient population.METHODS AND RESULTS: A total of 1,010 patients were enrolled at 40 clinical sites in Europe, including 24.9{\%} with medically treated diabetes, 50.0{\%} with Type B2/C lesions, 6.1{\%} with chronic total occlusion, 17.8{\%} with acute myocardial infarction (MI ≤24 hours pre-procedure), and 20.1{\%} with unstable angina. The target lesion was the culprit for ST-segment elevation MI in 7.3{\%} of patients. The one-year, per patient target vessel failure rate was 6.2{\%} (60/975), 3.4{\%} (33) being related to the PROMUS Element stent. Rates of cardiac death, MI, and Academic Research Consortium (ARC) definite/probable stent thrombosis were 1.7{\%}, 3.5{\%}, and 0.6{\%}, respectively. The target vessel revascularisation rate was 3.2{\%} (31/975), 2.1{\%} (20) being related to the PROMUS Element stent.CONCLUSIONS: In a large and relatively complex group of {"}real-world{"} patients, coronary artery revascularisation with the PROMUS Element everolimus-eluting stent provides favourable results with low event rates consistent with those reported for other contemporary drug-eluting stents.",
author = "Thomas, {Martyn R.} and Ralf Birkemeyer and Peter Schwimmbeck and Victor Legrand and Raul Moreno and Carlo Briguori and Nikos Werner and Ezio Bramucci and Imre Ungi and Gert Richardt and Underwood, {Paul L.} and Dawkins, {Keith D.}",
year = "2015",
month = "3",
day = "1",
doi = "10.4244/EIJY15M01_07",
language = "English",
volume = "10",
pages = "1267--1271",
journal = "EuroIntervention",
issn = "1774-024X",
publisher = "EuroPCR",
number = "11",

}

TY - JOUR

T1 - One-year outcomes in 1,010 unselected patients treated with the PROMUS Element everolimus-eluting stent

T2 - the multicentre PROMUS Element European Post-Approval Surveillance Study

AU - Thomas, Martyn R.

AU - Birkemeyer, Ralf

AU - Schwimmbeck, Peter

AU - Legrand, Victor

AU - Moreno, Raul

AU - Briguori, Carlo

AU - Werner, Nikos

AU - Bramucci, Ezio

AU - Ungi, Imre

AU - Richardt, Gert

AU - Underwood, Paul L.

AU - Dawkins, Keith D.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - AIMS: The PROMUS™ Element™ European Post-Approval Surveillance Study (PE-Prove) is a prospective, open-label, multicentre observational study designed to assess outcomes following PROMUS Element everolimus-eluting stent implantation in an unselected patient population.METHODS AND RESULTS: A total of 1,010 patients were enrolled at 40 clinical sites in Europe, including 24.9% with medically treated diabetes, 50.0% with Type B2/C lesions, 6.1% with chronic total occlusion, 17.8% with acute myocardial infarction (MI ≤24 hours pre-procedure), and 20.1% with unstable angina. The target lesion was the culprit for ST-segment elevation MI in 7.3% of patients. The one-year, per patient target vessel failure rate was 6.2% (60/975), 3.4% (33) being related to the PROMUS Element stent. Rates of cardiac death, MI, and Academic Research Consortium (ARC) definite/probable stent thrombosis were 1.7%, 3.5%, and 0.6%, respectively. The target vessel revascularisation rate was 3.2% (31/975), 2.1% (20) being related to the PROMUS Element stent.CONCLUSIONS: In a large and relatively complex group of "real-world" patients, coronary artery revascularisation with the PROMUS Element everolimus-eluting stent provides favourable results with low event rates consistent with those reported for other contemporary drug-eluting stents.

AB - AIMS: The PROMUS™ Element™ European Post-Approval Surveillance Study (PE-Prove) is a prospective, open-label, multicentre observational study designed to assess outcomes following PROMUS Element everolimus-eluting stent implantation in an unselected patient population.METHODS AND RESULTS: A total of 1,010 patients were enrolled at 40 clinical sites in Europe, including 24.9% with medically treated diabetes, 50.0% with Type B2/C lesions, 6.1% with chronic total occlusion, 17.8% with acute myocardial infarction (MI ≤24 hours pre-procedure), and 20.1% with unstable angina. The target lesion was the culprit for ST-segment elevation MI in 7.3% of patients. The one-year, per patient target vessel failure rate was 6.2% (60/975), 3.4% (33) being related to the PROMUS Element stent. Rates of cardiac death, MI, and Academic Research Consortium (ARC) definite/probable stent thrombosis were 1.7%, 3.5%, and 0.6%, respectively. The target vessel revascularisation rate was 3.2% (31/975), 2.1% (20) being related to the PROMUS Element stent.CONCLUSIONS: In a large and relatively complex group of "real-world" patients, coronary artery revascularisation with the PROMUS Element everolimus-eluting stent provides favourable results with low event rates consistent with those reported for other contemporary drug-eluting stents.

UR - http://www.scopus.com/inward/record.url?scp=84952308966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952308966&partnerID=8YFLogxK

U2 - 10.4244/EIJY15M01_07

DO - 10.4244/EIJY15M01_07

M3 - Article

C2 - 25631367

VL - 10

SP - 1267

EP - 1271

JO - EuroIntervention

JF - EuroIntervention

SN - 1774-024X

IS - 11

ER -